Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462183 | 0.80 | TDP1 (0.44) | TDP1L3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL14519215 | 0.75 | NPC1 (0.47) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL11322012 | 0.74 | ELANE (0.54) | ALDH1A1NPC1RAB9AKMT2AELANE | |
| SCHEMBL30579886 | 0.70 | TDP1 (0.64) | TDP1ALDH1A1NPC1RAB9ANPBWR1 | |
| SCHEMBL31051613 | 0.69 | CA12 (0.46) | TDP1L3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL7366940 | 0.68 | NPC1 (0.50) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL7589532 | 0.68 | NPC1 (0.50) | TDP1ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL7889097 | 0.66 | NPC1 (0.51) | TDP1ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL5696756 | 0.66 | CA4 (0.61) | L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1398350 | 0.65 | CES2 (0.58) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130108554-A1 | CONTRAST AGENTS | NORTHWESTERN UNIVERSITY (US) | 2013-05-02 | — | — | US | disclosed |
| US-8337813-B2 | Contrast agents | NORTHWESTERN UNIVERSITY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090269284-A1 | CONTRAST AGENTS | NORTHWESTERN UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009036441-A2 | CONTRAST AGENTS | NORTHWESTERN UNIVERSITY (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1613351-A1 | TARGETED AGENTS FOR BOTH PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY | MPA Technologies, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1558137-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | Research Corporation Technologies (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040247527-A1 | Multifunctional photodynamic agents for treating of disease | MPA TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004080483-A1 | TARGETED AGENTS FOR BOTH PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY | MPA TECHNOLOGIES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040146463-A1 | Functional MRI agents for cancer imaging | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-29 | — | — | US | disclosed |
| WO-2004037210-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6673333-B1 | COMPRISING A FIRST GD(III) ION BOUND TO A FIRST CHELATOR; GD(III) ION HAS COORDINATION ATOMS IN AT LEAST 7 COORDINATION SITES; BOUND TO TUMOR ASSOCIATED ACTIVATIVLE GUARDING MOIETY | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | METAPROBE, INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1278552-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002080757-A2 | NOVEL FUNCTIONAL AGENTS FOR MAGNETIC RESONANCE IMAGING | METAPROBE, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001082976-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | FABP7, RXFP1, MRGPRX2 | TDP1 3521/4885L3MBTL1 4204/4885ALDH1A1 3937/4885 |
| US-20040146463-A1 | Functional MRI agents for cancer imaging | TSG101, SMARCE1, SMARCA1 | TDP1 3140/4885L3MBTL1 3447/4885ALDH1A1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.